Abstract
ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1059-1064 |
| Number of pages | 6 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 16 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2 2016 |
Fingerprint
Keywords
- ankylosing spondylitis
- Axial spondyloarthritis
- certolizumab pegol
- non-radiographic spondyloarthritis
ASJC Scopus subject areas
- Pharmacology
- Clinical Biochemistry
- Drug Discovery
Cite this
Certolizumab pegol for treating axial spondyloarthritis. / Desmarais, Julianna; Beier, Secia; Deodhar, Atulya (Atul).
In: Expert Opinion on Biological Therapy, Vol. 16, No. 8, 02.08.2016, p. 1059-1064.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Certolizumab pegol for treating axial spondyloarthritis
AU - Desmarais, Julianna
AU - Beier, Secia
AU - Deodhar, Atulya (Atul)
PY - 2016/8/2
Y1 - 2016/8/2
N2 - ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.
AB - ABSTRACT: Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. Areas covered: The pharmacologic properties of CZP were reviewed. Data regarding the use and efficacy of CZP in axSpA were reviewed. Quality of life outcomes and safety profiles of CZP in axSpA patients were discussed as well. Expertopinion: While there are several biologics with evidence for improved outcomes in AS, there is less evidence for biologic medications that have good efficacy in nr-axSpA. CZP has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes in both conditions, with a tolerable safety profile.
KW - ankylosing spondylitis
KW - Axial spondyloarthritis
KW - certolizumab pegol
KW - non-radiographic spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=84978976235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978976235&partnerID=8YFLogxK
U2 - 10.1080/14712598.2016.1205581
DO - 10.1080/14712598.2016.1205581
M3 - Article
VL - 16
SP - 1059
EP - 1064
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 8
ER -